Our Network of Consultants

An AI and computational life sciences expert with approximately 11 years of experience across artificial intelligence, machine learning, bioinformatics, computational biology, oncology, genomics, multi-omics, spatial biology, and scientific software. He Founder and AI Systems Lead at Lumenix and a PhD candidate at Seoul National University in Molecular Medicine and Biopharmaceutical Sciences.

His work spans scientific AI and agentic workflows, computational oncology, biomarker and target discovery, precision medicine, spatial and single-cell analysis, multimodal biomedical data integration, AI evaluation, and pharmaceutical R&D. He has led or contributed to projects involving thyroid cancer resistance, exosomal miRNA diagnostics in lung cancer, colorectal cancer biology, pre-metastatic niche research, spatially informed ADC target discovery, and large-scale multimodal biomedical cohorts.

His technical background includes Python, PyTorch, TensorFlow, scikit-learn, XGBoost, graph neural networks, Transformers, FastAPI, SQL, Docker, cloud/GPU infrastructure, LangGraph, LangChain, MCP, function calling, multi-agent orchestration, evaluation frameworks, and reproducible scientific workflows.

He can advise clients on AI strategy and implementation, scientific AI, AI agents, bioinformatics, computational biology, oncology, multi-omics, biomarker and target discovery, precision medicine, and AI-enabled pharmaceutical and biomedical R&D.

I am an experienced engineering consultant and technical leader with more than ten years’ experience delivering complex laboratory automation, robotics and advanced machinery projects across the life-science and industrial sectors.

I provide independent support to organisations developing, specifying, integrating or deploying automated systems. My work focuses on turning complex technical challenges into practical, safe and deliverable engineering solutions.

My capabilities include laboratory automation strategy, system architecture, requirements definition, equipment specification, supplier selection, hardware integration, technical project leadership and engineering risk management. I also support machinery safety, risk assessment, electrical design coordination, functional interfaces, technical documentation and the development of robust service and maintenance strategies.

I have extensive experience leading multidisciplinary teams across mechanical, electrical, software and controls engineering. My background includes managing the delivery of bespoke laboratory automation platforms, robotic systems and integrated equipment for demanding life-science applications. I am particularly experienced in resolving interface issues between equipment suppliers, automation providers and end users, where responsibilities, requirements and technical boundaries are not clearly defined.

I can support clients at any stage of the automation lifecycle, from early feasibility and concept development through detailed design, supplier management, commissioning, validation support and project recovery. I also provide independent technical input during procurement, customer discussions, design reviews and investment decisions.

My approach combines systems thinking with practical delivery experience. I aim to ensure that solutions are not only technically capable, but also safe, supportable, commercially realistic and suitable for deployment in an operational laboratory environment.

I hold a degree in engineering and have held senior engineering management and technical leadership roles within laboratory automation and biotechnology organisations. I now work independently, supporting clients on advisory assignments, defined work packages and fractional engineering leadership engagements.

I am an experienced immunology scientist and strategic research professional with over seven years of experience translating complex science into actionable solutions for gene and cell therapy innovation. My expertise spans target discovery, assay development, and preclinical validation in oncology and autoimmune disease. I currently lead cross-functional research guiding data-driven decisions that accelerate candidate selection and advance therapeutic programs toward clinical development.

I bring a unique blend of technical depth and strategic perspective, skilled in multi-colour flow cytometry, viral vector design, and in vivo preclinical models, while adept at troubleshooting, stakeholder communication, and aligning scientific outputs with project milestones. I excel at bridging science and strategy, supporting decision-making that drives efficiency, innovation, and measurable outcomes.

During my PhD at King’s College London, I developed a novel non-invasive quantification method for CAR T cell activity and presented my work internationally. My research has been published in Nature Medicine, Cancer Cell, and Science Advances. I am passionate about applying scientific insight and strategic problem-solving to help organisations optimise R&D strategies, de-risk innovation, and translate discovery into real therapeutic and business value.

• Director-level Competitive Intelligence (CI) leader with 14+ years of pharma/ biotech industry experience in oncology and immuno-oncology (IO). Including over 6 and a half years specialising in competitive intelligence,
clinical data insights, evidence synthesis, and strategic analysis to inform evidence-based decision-making, and over 7 years in preclinical drug discovery.
• Deep domain expertise in oncology therapeutics (for solid tumours and haematological malignancies), covering a global pipeline, with acute understanding of several treatment modalities including antibody-drug conjugates, monoclonal antibodies, bispecifics, chemotherapy, hormonal therapy, cell therapy and small molecules.
• 7+ years of leadership experience on various dimensions, including team leadership, line managing direct reports, leading an IO CI function, expanding the scope and influence of an insights function, drug discovery
project leadership, project management, stakeholder and external vendor management, hiring and mentoring junior colleagues, fostering capability building within a team, delegating work effectively, improving integrated
insights processes (Six Sigma Yellow Belt), and driving adoption of new systems to improve evidence-based decision-making and maximise the strategic value of competitor information.
• Proven track record of collaborating with senior leadership (Senior Director, VP and C-suite) and other key partners from several functions (medical, clinical development, Business Development, publications, and Investor
Relations), to deliver actionable insights, and support clinical trial planning, portfolio asset prioritisation, lifecycle management, and corporate strategy activities.
• Led or supported numerous initiatives aiming to develop commercial and clinical strategy, including epidemiology analyses for patient population sizing, updating standard of care (SOC) efficacy hurdle in several
target product profiles (TPPs), providing evidence for trial diversity planning, or indication prioritisation.
• Extensive experience monitoring competitor pipeline assets (from preclinical research through commercialisation), integrating and analysing scientific literature, clinical, regulatory, commercial, and
investment banking reports data, into recommendations and delivering forward-looking competitive insights that shape clinical strategy and inform portfolio investment decisions.
• Specialised in translating complex quantitative and qualitative scientific, clinical trial, or industry data into high quality executive-level deliverables and communicating this information effectively to technical and
non-technical stakeholders, to ensure a full understanding of the constantly evolving oncology landscape.
• Proficiency with best-in-class external data sources (Norstella suite, Clarivate tools, GlobalData, Clinicaltrials.gov, Article Galaxy, Kantar, Medline, Embase, PubMed, Scopus, …), and data visualisation tools (Power BI, Tableau), and statistical tools (GraphPad Prism, Minitab, Excel) used in leading Pharma companies like AstraZeneca.
• Combines strong scientific background in IO research and development, analytical rigour, and critical thinking with a proven ability to influence cross-functional decision-making without authority, and providing transparency and respectful challenge to key decision makers in a matrixed global environment.
• Strong business acumen, and deep understanding of strategic corporate priorities, having supported fundraising activities, led scientific and strategic due diligence on 2 merger and acquisition transactions (including one
leading to an IPO on Nasdaq), supported differentiation messaging for investor relations communication, and helped VP and C-suite senior leaders make data-driven decisions with agility and impact.

Industry-focused structural biologist, team leader, and consultant with over 14 years of experience across biotech startups, pharma, and world-class academic institutes (EMBL, University of Bristol). Proven expertise in end-to-end vaccine and biologics development, with a specialization in protein engineering, molecular design, advanced vaccine platforms (VLPs), and multiprotein complexes. Strong track record of translating complex structural biology into scalable, deployable products, bridging the gap between R&D discovery and clinical manufacturing (CMC, USP/DSP, and CDMO tech transfer). Offers high-impact technical due diligence and strategic advisory to de-risk early-stage pipelines and accelerate time-to-market.

I work with life sciences and biotech companies as a fractional CFO and finance director. With 16 years of experience across EMEA operations including financial director and supply chain finance roles within global life sciences businesses, I bring enterprise level finance capability to growing companies without the cost of a full time hire.
I help founders and leadership teams with investor ready financial reporting, budgeting and forecasting, audit readiness, cash flow management, board reporting, EMEA multi entity operations and UK subsidiary setup for overseas businesses.
I am dual qualified ACA and FCCA with an Executive MBA from London Business School. I work with companies typically between £5m and £50m revenue at key growth and funding stages.

With over a decade of experience in Sales, Account Management, and Business Development across Europe, I bring a proven track record of growing revenue, structuring global sales operations, and managing complex biopharmaceutical relationships. My expertise spans both services and capital equipment (CAPEX) sales, with a consistent history of exceeding targets and closing multimillion-pound deals at executive level.

I currently operate as a Business Development and Sales Consultant for Cellevate AB and LiveDrop Bio, where I designed and implemented complete business development strategies, built CRM systems and performance dashboards, and positioned the companies among key academic and biopharma stakeholders. My recent achievements include generating leads and converting them into purchase orders through strong technical presentations and relationship-building with KOLs, CROs, and manufacturing partners.

Previously, as Global Key Account Manager at Miltenyi Biotec, I managed six global customers totaling 23 international sites, negotiated supply agreements, and developed multi-year growth strategies. I notably closed a £3.3 million CAPEX deal within two weeks and contributed €35 million toward the 2024 revenue plan. At Sartorius Stedim, I led high-value accounts across France, Benelux, and the UK, expanding revenue by more than 200% year-on-year while coordinating multi-site collaborations across R&D and manufacturing.

My career demonstrates a unique combination of scientific literacy and commercial strategy. I began in technical sales roles with Sartorius and BD, where I introduced innovative single-cell and flow cytometry technologies, managed market entry strategies, and won back blacklisted accounts through consultative negotiation. Over time, I transitioned into strategic sales leadership—defining go-to-market frameworks, establishing KPIs, and mentoring sales representatives across divisions and regions.

Fluent in both English and French, I excel in cross-cultural communication and high-level stakeholder engagement. My skill set spans consultative and strategic selling, global account mapping, contract negotiation, and profit planning. Equipped with deep knowledge of the biopharma value chain—from cell and gene therapy manufacturing to clinical and CDMO partnerships—I operate effectively within matrixed organizations and thrive in fast-evolving innovation environments.

Certified in advanced selling methodologies (Sandler, Miller Heiman, Mercuri) and completing PRINCE2 accreditation, I combine technical expertise, legal understanding, and business acumen to deliver sustainable commercial growth in the life sciences sector.

My area of study is the intersection of clinical neuroscience, translational pharmacology, and computational biomarker discovery. I am a PhD candidate investigating how glymphatic and meningeal–lymphatic pathways relate to neuroinflammation in humans. I focus on immune-cell phenotyping and cell-free markers that may index inflammatory activity and neurodegenerative trajectories. Alongside sampling development, I contribute to assay and workflow optimisation for mass-spectrometry-ready proteomics, with an emphasis on automation, quality control, and reproducibility.

My pharmacology and drug-safety foundation was built through an MRes in Biological Science and Translational Medicine. I examined dose- and time-dependent paracetamol-induced kidney injury in renal cell models, differentiating apoptotic and necrotic mechanisms and linking experimental readouts to clinically relevant nephrotoxicity questions. I completed a systematic review on cilastatin as a renoprotective strategy and critically evaluated in vitro acute kidney injury models for translational validity. I also gained ward-level exposure as a Clinical Research Associate in nephrology, aligning laboratory findings with real-world clinical pathways and multidisciplinary decision-making.

From an industry and communications perspective, I have experience in medical affairs-adjacent work, including market analysis to support launch planning in an ophthalmic pharmaceutical company and the development of compliant training materials with medical teams. I have delivered conference and hospital presentations, tailoring complex findings to both clinical and public audiences, and I have completed structured projects on European compliance frameworks, which underpins my approach to regulatorily aware medical writing.

Computationally, I build end-to-end machine-learning workflows in Python and R for noisy, high-dimensional datasets, particularly proteomics and multimodal clinical data. My toolkit spans supervised learning, unsupervised clustering, and dimensionality reduction.

Overall, my expertise is translating complex biomedical and quantitative evidence into actionable deliverables, supported by an MBA in Clinical Leadership and a strong biochemistry foundation, including earlier research on TEX12 expression in somatic and cancer models.

During 16 years as a Ph.D. immunologist in the Life Science sector, I gained extensive expertise in the areas of inflammation/autoimmunity, immuno-oncology, MicroRNA therapeutics as well as vaccine platforms. I established a long-standing track record in lead identification and biomarker discovery work.

Working in the small-biotech environment, I embraced an entrepreneurial mindset and the necessity of wearing multiple hats across R&D, quickly adapting to an agile, fast-paced atmosphere to drive early-stage innovation. This hands-on approach and broad exposure to various functions, offered me a holistic view of the pipeline and the direct impact of my work. Transitioning to the corporate environment of a world-leading pharmaceutical company, I was able to utilize my diverse background while benefiting from the processes, resources, and expertise that define large organizations. In this highly impactful system, I was fortunate to lead and contributed to large-scale, international, high-priority projects with my work being instrumental to achieve set milestones.

As a consultant, I will be able to support activities across the full spectrum of the R&D pipeline, including, but not limited to:
• Identifying innovative new therapeutic concepts for immunological indications and pipeline expansion
• Developing mechanistic- and unmet-need-based research strategy to advance characterization of therapeutic targets and biomarkers
• Spearheading the development of novel in-vivo and ex-vivo animal and pathway models
• Supporting and guiding laboratory-based scientists in planning, execution and data analysis of in-vitro and in-vivo studies
• Bridging cross-functional/translational work with internal stakeholders as well as key external experts

KEY STRENGTH AND SKILLS
• Extensive expertise in early-to late-stage immunological research in the context of immuno-oncology and inflammation/autoimmunity
• Highly experienced in working cross functional within global project teams and with external partners/CROs
• Leadership experience by managing and mentoring teams and individual scientists
• Deep knowledge in cell- and molecular biology (with a vast array of in-vitro and in-vivo immune-bioassays), as well as characterization of disease relevant signaling pathways
• Extensive background in various animal models and multiple species
• Highly proficient in data analysis, -management, and -interpretation
• Excellent verbal and written communication- and presentation skills

Over 35 years experience in life science research and the life science tools industry. 25+ years experience as a senior corporate executive in leading public and private life science tools companies, as well as board service and consulting over the past 10 years. A primary focus has been in corporate development and merger & acquisition.

Specialties: corporate development, merger and acquisition, and strategic planning in the life science tools industry

With over 14 years of experience in the biotechnology and pharmaceutical sectors, I have established myself as a dynamic and results-driven leader, excelling in roles that demand strategic vision, scientific acumen, and exceptional project management skills. My career has been marked by significant contributions to drug discovery, innovation management, and business development, with a proven track record of driving growth and fostering client loyalty.

As Chief Business Officer in a CRO, I spearheaded business development initiatives, proactively engaging potential clients through targeted outreach campaigns. I successfully managed the entire sales cycle and secured contracts with biotech and major pharmaceutical companies. My ability to develop comprehensive proposals, aligning technical and financial aspects with client needs, ensured effective project management and client satisfaction. I represented the company's key assets at international congresses, further enhancing our market presence.

In my concurrent role as Chief Innovation Officer, I secured substantial funding for R&D projects through programs like Eurostar. My expertise in providing scientific and technical guidance to stakeholders has been instrumental in driving innovation and maintaining high standards of project execution.

Prior to these roles, as Chief Project Officer, I spearheaded drug discovery research projects, evaluating the efficacy, mechanism of action, and proof of concept for various candidates, including viruses, antibodies, small molecules, and vaccines. I managed cross-functional teams, budgets, timelines, and deliverables, ensuring project completion and regulatory compliance. My ability to analyze data and my deep expertise in flow cytometry, in vitro assays, immunology, mouse models and preclinical pharmacology evaluation allowed me to present comprehensive reports to clients and ensure project success and client satisfaction.

My academic foundation includes a PhD in immuno-oncology and a tenure as a Research Scientist at INSERM. I secured two post-doctoral grants and authored several peer-reviewed publications, further solidifying my scientific expertise.

Throughout my career, I have demonstrated a strong commitment to leadership, team collaboration, and client-centric approaches. My ability to fuse scientific knowledge with strategic business acumen has enabled me to drive impactful projects and foster long-term client relationships. I am eager to bring this unique blend of skills and experiences to new challenges, continuing to innovate and deliver exceptional results in the biotechnology and pharmaceutical sectors.

As a strategic life sciences leader with over 14 years of experience in oncology, immuno-oncology, and cell and gene therapy, I am passionate about advancing innovative therapies that improve patient outcomes. My journey in biotech has been defined by a hands-on approach to discovery research, product development, and regulatory strategy, taking concepts from the lab bench to clinical trials.

Throughout my career, I’ve had the privilege of leading and contributing to groundbreaking projects. At TC BioPharm, I played a pivotal role in the FDA approval of an allogeneic gamma delta T cell therapy and the preclinical development of next-generation CAR-T products. My expertise in developing complex assays and driving exploratory clinical analyses has been critical in achieving key milestones, including advancing a phase 2/3 AML clinical trial.

As a consultant, I leverage my experience to guide biotech companies in refining development strategies and bridging preclinical and clinical efforts. From conducting due diligence for investments to streamlining development pathways, I provide actionable insights that reduce timelines and costs while maintaining scientific and regulatory rigour.
Collaboration is at the heart of this effort. I thrive in cross-functional teams, ensuring seamless integration across R&D, clinical, regulatory, and manufacturing functions. I also enjoy mentoring, developing talent, and fostering team innovation and resilience.

I actively contribute to the scientific community, having presented at international conferences such as the Gamma Delta T Cell Therapies Summit and the Allogeneic Cell Therapies Summit. My academic foundation, with a PhD in Medicine from the University of Glasgow, further underpins my technical expertise and commitment to translating research into impactful therapies.

Joining this network aligns with my drive to connect with like-minded professionals with a vision for transforming healthcare. I am eager to contribute my knowledge, learn from peers, and explore opportunities for collaboration that can accelerate therapeutic development and benefit patients worldwide.

Senior Life Sciences Executive and Technical Expert with 15+ years of experience driving innovation in biotechnology. Proven track record in building and scaling successful ventures, specializing in cell biology, automation, and AI-powered solutions. Currently serving as CEO of an iPSC technology company, while offering strategic consulting to emerging life science ventures.

Technical Expertise:
- Cell culture and cell line development (CLD)
- Extensive experience with cancer, CHO, HEK, cultured meat and iPSC cell lines
- Developing and validating automation and high-throughput AI-based imaging instrumentation
- Cell line optimization, immortalisation, engineering and characterization

Molecular & Synthetic Biology:
- Gene editing and genetic engineering
- Vector design and production
- Protein expression systems

Leadership Experience:
- Founded and scaled an iPSC quality control company from concept to market
- Led cross-functional teams of scientists, software engineers and engineers
- Developed and implemented automated laboratory workflows
- Successfully navigated multiple funding rounds and strategic partnerships

Industry Applications:
- Drug discovery and development
- Diagnostic platform development
- Viral vector manufacturing
- Stem cell technologies
- Vaccine development
- Recombinant protein production

Consulting Services:
- Strategic Planning
- Scientific advice
- Market entry strategy
- Technology road-mapping
- IP portfolio development
- Laboratory Operations
- Design and construction optimization
- Workflow automation

A PhD consultant in the biotechnology and life sciences industry with over 17 years of experience working internationally. Specializing in customer insights, market-driven product development and strategic marketing, with expertise in genomic medicine, gene therapy, cell therapy, nanomedicine, NGS, molecular diagnostics, oncology, and more. Held leadership positions in biotech and life sciences companies in Canada, US and UK, including Abcam, STEMCELL Technologies, Thermo Fisher Scientific, Cytiva/Danaher.

I have a a D.Phil. in Biochemistry from the University of Oxford with first author publication in Nature Immunology; an MSc from University of Toronto and a BSc (Honours) from University of British Columbia.

Consulting Services include:
Voice of Customer/Customer Insights
Market Driven Product Requirements
Value Propositions and Product Positioning
Product-Market fit
Competitor Landscape Assessments
Pricing Strategies
Go to Market Strategies

I consider myself an "all-rounder," but as a consultant, I focus on helping clients with their marketing, bringing my experience from the last 25 years working in a range of commercial roles at top life science companies. After a Ph.D. and post-docs, I started my first non-lab role in tech support, then developed my business skills in sales and business development before progressing to senior management positions in marketing, product management, and business unit management, where I founded and led international teams.

I've worked with commercial and technical teams at >200 life science companies - distributors, manufacturers, and OEM resellers in public companies, private companies, and startups. As a consultant, I take on a range of commercial projects, mainly in the marketing/product management realm, specializing in writing engaging content to attract and convert customers, including websites and sales tools.

With a distinguished background, which includes a PhD and an eMBA, I seamlessly integrate scientific and technical expertise with a profound understanding of global business strategy in chemistry for the biology, assay development and detection methods.